Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC

INTRODUCTION: Gene rearrangements are frequent oncologic drivers in NSCLC, and many are suitable for treatment with Food and Drug Administration–approved or experimental targeted therapies. We evaluated the accuracy, specimen acceptance profile, and limits of detection of a rapid fusion assay (Idyll...

Descripción completa

Detalles Bibliográficos
Autores principales: Buglioni, Alessia, Caffes, Patricia L., Hessler, Mark G., Mansfield, Aaron S., Lo, Ying-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758522/
https://www.ncbi.nlm.nih.gov/pubmed/36536899
http://dx.doi.org/10.1016/j.jtocrr.2022.100434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758522/
https://www.ncbi.nlm.nih.gov/pubmed/36536899
http://dx.doi.org/10.1016/j.jtocrr.2022.100434

Ejemplares similares